People | February 23, 2022
Sumitomo Dainippon Pharma Oncology appoints Jatin J. Shah as Chief Medical Officer
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
he financing was significantly oversubscribed with high demand from both existing and new investors.
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets
New inhalers would have near-zero Global Warming Potential propellant
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.
Subscribe To Our Newsletter & Stay Updated
